MVS Solutions - The Technology Realization Company


Technology Marketplace & Technology Clearinghouse

Technology & Intellectual Property (IP) Licensing, Acquisition and Development in the Biotech, High Tech, Medical Technology and Related Industries

MVS Solutions licenses, sells, acquires and develops products and technologies on behalf of our clients, ourselves and our partners in the biotech, chemistry, healthcare, life sciences, medical, pharmaceutical and related industries. The following technologies are currently available for licensing or acquisition:


Search Clearinghouse


Licensing Opportunities

Contact Us    CardionomicsTM Human Heart Failure Detection Technology

Microarrays provide a versatile platform for utilizing information from the Human Genome Project to benefit human health. However, to date this technique has been shown to have low specificity, sensitivity, and reproducibility when using human samples for identification of genes involved in the pathogenesis of heat failure. This is evident in conflicting published data identifying diverse gene expression patterns by means of array analysis using human heart failure tissue. The extent to which this deficiency is linked to individual differences such as sex, race, diverse etiology of the disease, drug therapy vs. tissue collection and handling has not been fully addressed until now.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us

Contact Us    Gold Nanoparticles as Improved X-Ray Contrast Agents

1.9 nm gold nanoparticles are a new type of contrast agent for X-ray imaging, providing higher contrast and enabling imaging in critical situations, such as chest pain admissions, in patients not suited to iodine-based agents such as obese patients, patients with allergic reactions to iodine, and immunologically compromised patients. Gold nanoparticles overcome many of the limitations of current triiodobenzene derivatives for use as X-ray contrast agents. Gold has higher X-ray absorption than iodine with less bone and tissue interference, thus achieving better contrast with lower X-ray dose. Because nanoparticles clear the blood more slowly than iodine agents, they permit longer imaging times. Gold can be concentrated to 1.5 g Au/mL, 5 x higher than iodine agents. With 3x higher absorption, this enables 10x or 15x higher opacity. In contrast to iodine-based reagents, viscosity is very low, reducing the risk of vascular damage during catheterization.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    New Fusion Tag for Site-specific Conjugation of Payloads to Targeting Proteins

Targeted delivery of therapeutic and diagnostic agents might significantly decrease systemic toxicity, increase efficacy of new and old drugs, support development of personalized medicine, and provide new uses for existing therapeutic proteins. Although many proteins can be used for targeted delivery, random conjugation of a "payload" to a protein creates heterogeneous products that are not well-suited for development and for regulatory approval. This invention eliminates random conjugation and provides a strategy for development of functionally active, homogeneous protein-based products. In this strategy, a protein is expressed with a humanized 15-aa cysteine-containing tag (Cys-tag), and a payload is site-specifically conjugated to a cysteine residue in Cys-tag via thiol-directed chemistries. Cys-tag is compatible with every protein tested so far, and accommodates payloads as different as drugs, contrast agents, dendrimers, liposomes, and functional proteins.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Novel Agents for Imaging Receptors for Vascular Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) is the key regulator of angiogenesis and overexpressed VEGF receptors play the crucial role in the onset and progression of tumor angiogenesis. receptors are the primary targets of tremendous efforts to develop inhibitors of angiogenesis. However, these receptors are not used as biomarkers for prescribing or monitoring anti-angiogenic therapy due to a lack of methods for assessment of their prevalence. This invention provides molecular probes for PET, SPECT, and NIRF imaging VEGF receptors. The probes are based on a novel single-chain VEGF (scVEGF) expressed with a proprietary cysteine-containing tag for site-specific conjugation of contrast agents. VEGF-based probes bind to and internalized by VEGF receptors as effectively as parental VEGF, providing unique opportunities for non-invasive imaging VEGF receptors in vivo. Information on prevalence of VEGF receptors in patients might lead to evidence-based selection of candidates for anti-angiogenic therapy, facilitate design of personalized treatment regiments, enable early diagnostics and discrimination between benign and malignant lesions.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Beta-Amyloid Binding Factors and Inhibitors Thereof

The present invention relates to a VEGF polypeptide that binds to beta-amyloid. The present invention also relates to a compound that sequesters beta-amyloid. And conversely, the invention relates to a compound that sequesters VEGF. Thus, the present invention also relates to a method of screening for a compound that inhibits the binding of VEGF to beta-amyloid, and thus relates to diagnosis and treatment of Alzheimer's Disease.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Novel Peptides for Inhibiting the Formation of Beta-Amyloid

This invention provides short peptides that inhibit formation of beta-amyloid from APP by protecting APP from cleavage by beta-secretase. More specifically, the invention provides compounds that bind to a short region of APP containing the cleavage site of beta-secretase without affecting the enzyme. The blocking compounds act only on the processing of APP, thereby providing a preventative and therapeutic agents having better benefit while minimizing the potential side-effects caused by the inhibition of the enzyme function such as processing of other proteins and also by the inhibition of isoforms of beta-secretase.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Therapeutic Peptides Enhancing an Immune Response

This invention provides immune-enhancing peptides that induce the generation of superoxides in human body, and synthetic method for the peptides. Immune-enhancing peptides induce an immune response in human body by enhancing monocyte or neutrophil to promote cell mobility and to produce the superoxides. Thus, the immune-enhancing peptide can be used for a therapeutic agent of immune-related diseases.

Download additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Ligand Profiling and Identification

The present application discloses a method of identifying an active agent in a sample, which steps include subjecting the sample to a plurality of separation principles in parallel, obtaining an active fraction from each separation principle, and profiling physiochemical properties of the active fraction so as to obtain the agent that is common in each of the fractions, thereby identifying the agent of interest.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Leukocyte-Activating Peptides for Immunotherapy

This invention provides immunocyte-stimulating peptides and synthetic methods for the peptides. The peptide induces an immune response by playing a key role in the movement of target cell, secretion of arachiodonic acid, the generation of superoxides, or the activating of phospholiphase. The peptide can be used for immune-related disease.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Immune-Modulating Peptide

Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Genes of IL-12p40 Subunit Mutated for Improving the Activity of IL-12 and Use Thereof for DNA Vaccine Adjuvant

The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12 (interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL-12p70 by making mutation at Asn-222 (human) or Asn-220 (mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of the active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy to various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    rIL-12 Encapsulated with Biodegradable Microspheres as a Vaccine Adjuvant

This invention provides a component to enhance vaccine-specific T helper 1 immune responses by delivery of encapsulated rIL-12 with biodegradable microspheres as a molecular vaccine adjuvant. As a strategy to achieve the persistence of IL-12 in vivo, we designed rIL-12-encapsulated biodegradable microspheres, and the co-delivery of these microspheres induces stronger and longer-lasting T helper 1 immune responses at a great degree than IL-12 DNA or unmodified rIL-12 protein.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Therapeutic DNA Vaccine for Chronic Hepatitis B

The present invention provides a therapeutic DNA vaccine and vaccine treatment method for chronic hepatitis B. A therapeutic DNA vaccine, HB-100, is capable of inducing T helper type1 (Th1) and cellular immune responses that are known to be required for resolution of chronic hepatitis B. HB-100 comprises 1) an efficient expression vector, 2) Hepatitis B Virus nucleotide sequences encoding most HBV antigens to induce polyclonal, multi-epitope specific T cell immune responses, 3) a genetically engineered cytokine Interleukin-12 to induce strong Th1 and cellular immune responses. The efficacy rate of combination therapy with lamivudine and HB-100 can reach more than 50%, whereas the efficacy of lamivudine alone was previously reported to be less than 20%.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    SIVmac239 Immunogenic Plasmids and AIDS DNA Vaccine Containing the Same

The present invention relates to immunogenic plasmids showing excellent expression efficiency of immunogens and immune efficacy in the SIVmac239/rhesus monkey model and AIDS human patients. Also, the present invention relates to DNA vaccines for prophylaxis or treatment of AIDS containing the above immunogenic plasmids.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Transcriptional Coactivator ASC-2

The present application describes a transgenic mouse whose genome comprises a DNA sequence unit encoding a fragment of Activating Signal Cointegrator-2 (ASC-2) comprising a C-terminal LXXLL motif polypeptide but not N-terminal LXXLL motif polypeptide, wherein Liver X Receptor (LXR) trans activating activity is inhibited, and uses therefor.

Download additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    2'-Deoxyuridine Derivatives Useful for Drug Delivery System

This invention provides 2'-deoxyuridine derivatives useful for hydrogelator and a synthesis thereof. Unlike nucleotide-based hydrogelator, the invention provides a novel hydrogelator which is stable under various conditions of pH and temperature. The low-molecular weight hydrogelator can be applied for drug delivery system.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Enhanced Targeting of Drug Delivery with Nucleoside Based Phospholipids

This invention provides phospholipids constituting nucleoside backbone such as adenine, guanine, cytosine, thymine, and uracil, etc. and the production method thereof. In addition, the invention provides a synthetic method of liposome which can recognize and adhere to each other through complementary binding between bases therein.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Molecular Transporters Mediating Cell Membrane Crossing

This invention provides inositol-based molecular transporters that can effectively mediate the plasma membrane and nuclear cell crossing for a variety of drugs. The transporters have the scaffold units having requisite number of attachment sites, and attachment of guanidine functionality through suitable linkers. In vitro model (COS7 and RAW264.7) for these arginine-rich molecular transporters demonstrates a high permeability through cytoplasm and the nuclear membrane, compared to that of arginine-poor intermediate.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Replicon-Based Screening Assay for HCV

This invention provides replicon-based screening assay for HCV. Transgenic mammalian cell host is developed to provide screening assay for pharmacologic inhibitors of HCV RNA replication. This invention has advantages over conventional screening assay based recombinant protease or polymerase of HCV. Since the host cell express HCV proteins whose level can be detected by replicon-based screening assay, leading to the development of highly accurate diagnostic test for HCV infection.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Gene That Controls Flowering Time in Monocotyledonous Plants

This technology identifies a novel gene that causes extremely early flowering at the callus stage in monocotyledonous such as rice. Mutant phenotypes observation suggests that the gene, OsMADS50, is an important flowering activator that controls various floral regulators in rice. Therefore this gene can be used to develop a new trait for high yield rice production in a way to avoid the flowering time, early or lately, during the period of insect activity.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Organ Preferential Genes Identified by T-DNA Insertional Mutagenesis of Rice

The present invention provides a method of producing rice lines that carry genes that have been modified by T-DNA/GUS based insertional mutagenesis. The GUS portion of the insert is promoterless, so that the GUS gene is expressed only when it is inserted into an active gene. In this way, organ preferential expression of various rice genes can be determined. The invention is also directed to the organ-preferential genes found by the T-DNA/GUS insertional mutagenesis method, as well as the proteins encoded by them. The invention also involves a database having information about the rice lines, such as the genes having the insert, the encoded proteins, the phenotypic characteristics of the mutant lines, and promoter activity of the tagged genes.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    T-DNA Insertional Mutant Pool of Japonica Rice

This technology provides 100,000 kinds of T-DNA insertional mutant line of Japonica rice and a database that contains information necessary for analyzing the function of rice genes. About 50,000 kinds of rice line obtained by activation tagging vector can induce dominant mutagenesis. In addition, 30,000 kinds of rice lines are obtained to induce recessive knock-out mutagenesis. The mutant lines also include various mutant lines regardless of inserted T-DNA, which provides a resource of breeding a new rice strain. The mutant lines can be applied for screening genes which can be effectively used for analyzing function of rice gene and their industrial application. Also, the mutant lines can be used for breeding a useful rice variety.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Development of Monocotyledonous Mutant by Using T-DNA Tagging Vector

This invention provides a method of preparing transformant by using T-DNA tagging vector functioning as an active marker and a gene trapper. In this technology, the function of a gene can be analyzed by inserting the T-DNA tagging vector on the boundary of the gene. When T-DNA is inserted and trapped in a gene, the expression profile of the gene can be analyzed. Thus, this technology provides a method of analyzing the functions of various plant genes, and a method of breeding a new variety of plant.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Genetic Modification of Plants for Enhanced Resistance and Decreased Uptake of Heavy Metals

The present invention relates to a method of producing transformants with enhanced resistance and decreased uptake of heavy metals, and a plant transformed with a P type ATPase ZntA gene that pumps out heavy metals from the cells. The transformants show better growth than wild type in environments contaminated with heavy metals and have lower heavy metal contents than wild type plants. Therefore, this method of transforming plants with ZntA or biologically active ZntA-like heavy metal pumping ATPases can be useful for developing plants for phytoremediation and also for a safe crop that has resistance to heavy metals and low heavy metal contents.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Transgenic Organism Expressing Fungal MRP-Like ABC Transporters

The present invention relates to an isolated DNA encoding fungal MRP (multidrug resistance associated protein) subfamily of ATP-binding cassette (ABC) transporter protein which confers organisms with resistance to and/or accumulation of toxic materials such as heavy metals and herbicides, vectors containing the isolated DNA, and organisms transformed with the isolated DNA. Organisms transformed with the fungal MRP subfamily of ABC transporters of the present invention can be used for remediation of environment polluted with toxic materials. For example, the transformed plants can be used for cleaning polluted soil or water, and thereby providing an environmentally-friendly way to remediate polluted resources with low cost.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Gene Controlling Flowering Time and Method for Controlling Flowering Time in Plants Using the Gene

The present invention relates to a gene regulating flowering time and a method for regulating flowering time in plants using the same. More particularly, the present invention relates to a COG gene having nucleotide sequence represented by SEQ ID No: 1 which is isolated from Arabidopsis thaliana, and a method for delaying flowering time of plants by overexpressing the gene, or for inducing early flowering by repressing an expression of the gene. The COG gene and the COG protein expressed therefrom according to the present invention are useful for improvement of flowering-associated character of plants, and for identification of flowering-associated genes or proteins in other plants, etc.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Gene Controlling Life Span of Leaves in Plants and Method for Controlling Life Span of Plants Using the Gene

The present invention relates to a gene regulating leaf longevity of plants and a method for regulating the longevity of plants using the same. More particularly, it relates to a ORE7 gene regulating leaf longevity of plants which has a nucleotide sequence represented by SEQ ID NO: 1, and to a method for regulating the longevity of plants, in which the ORE7 gene is introduced into the plants and overexpressed, thereby delaying senescence of the plants. Plants can be transformed with ORE7 gene according to the present invention, so that the longevity of the plants is extended, thereby improving productivity and storage efficiency of the plants. Furthermore, the ORE7 gene and an ORE7 protein expressed therefrom according to the present invention are useful for studies of senescence mechanisms, and for identification of senescence-associated genes or senescence inhibitory substances, in plants.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Novel Dendrimer Compound, A Biochop Using the Same and a Fabricating Method Thereof

The present invention relates to novel dendrimer compounds and method of producing a bio chip using the dendrimer. The present invention relates to the dendrimer that is represented by Chemical Formula 1, a substrate where the dendrimer is fixed, and the bio chip utilizing these compounds. [Chemical Formula I] wherein X is amine protecting group that is separated by acid, L is a spacer or -R-C(O)-NH- and R is substituted or unsubstituted hydrocarbon.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Enhanced AFM Tip for Force Measurement of Single Molecules

This technology provides the improved immobilization method that makes the binding force measurement between single molecules such as DNA-DNA using enhanced AFM tip. When AFM tip is modified with size-controlled dendrons, the tethered single strand is allowed to move around in solution enough to find its complementary part when the tip approaches the surface. Since single DNA molecule is attached to the apex of the AFM tip, precise measurement single DNA-DNA molecule interaction. This approach can also be applied to direct measurement of numerous biological processes such as DNA-protein and protein-receptor interaction.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Detection Method of Nucleic Acid Hybridization

The present invention relates to a detection method of DNA hybridization comprising: (a) preparing a oligo-plate by fixing capture probes onto a working electrode surface, (b) hybridizing the capture probes with target probes, (c) reacting a nucleic acid binding material specific to single-stranded nucleic acid or a double-stranded nucleic acid, (d) the nucleic acid binding material changes the charge state of the working electrode surface, and (e) measuring an electrochemical quantity depending on the charge state of the working electrode surface with an electrochemical method using an electroactive electrolytic condition.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    High Throughput Continuous Multiplex PCR Device

This invention provides high-throughput continuous-flow PCR device, consisting of a flow-through capillary and a cylindrical heating-block assembly. DNA amplification can be achieved by letting a PCR mixture continuously flow through a single channel passing repetitively through three constant temperature zones for melting, annealing, and extension. Also real time monitoring allows to overcome the limitation of conventional PCR device whose limitation is qualitative rather than quantitative. This invention also provides multiple PCR reactions for high-throughput, allowing us to develop a simple but powerful tool for genomics.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Focused Electrospray for Enhanced LC-MS Performance

Focused electrospray (FES) technology provides LC-MS coupling device to enhance detection limit as well as sensitivity for proteomics. In this technology, the charged droplets are focused within a 1-4 mm diameter tip well under atmospheric pressure. The FES produces a more uniform distribution of more fine grains or needles than the dried droplet, leading to the increased detection sensitivity. While the detection limit of the dried droplet method with MALDI-TOF instrument (Bruker) is typically ~50 fmole, the FES allows the detection limit of 5 fmole with angiotensin II using a 3 micron tip and 1 fmole with bradykinin using a 15 micron tip.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Phosphoramidites for the Synthesis of Oligodeoxynucleotides

This invention provides phosphoramidite compounds useful for the synthesis of commercially available DNA variants, and its production method. According to the invention, phosphoramidite compounds introduced with various functional groups such as 1,3-butandiol, benzyglycolate, lithocholic acid, etc., can be synthesized and can be used for synthesizing the oligodeoxynucleotides useful for various objects.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Method for Preparing Chiral Amines

Disclosed is a method of preparing chiral amine. The method includes reacting ketoxime, palladium, lipase, acyl-donating compound, and a tertiary amine to the prepare amide, and the amide is hydrolyzed.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Enzymes Coated With Ionic Liquid

Disclosed is an ionic liquid-coated enzyme, wherein the ionic liquid is an organic salt which presents as a liquid phase at a temperature of about 150 deg. C or below. The ionic liquid-coated enzyme according to the present invention remarkably improves enzyme functions, such as enantioselectivity and stability, when the enzyme which may be lipase is coated with an ionic liquid. Further, even in the case of when the ionic liquid-coated enzyme is reused, the enantiomeric excess, enantioselectivity, and activity are not degenerated. The coated enzyme is usable as a catalyst for providing a chiral intermediate required in the synthesis of chiral pesticides, medicines, natural chemicals, and so on.

Additional patent info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Recombinant Mussel Adhesive Protein for Medical and Industrial Application

This technology provides a protein expression system expressing highly value added proteins such as a mussel protein in E.coli by genetic technology. This technology allows to produce the mussel adhesive protein at high yield and to improve a separation and purification process, resulting in large scale production and purification of mussel adhesive suitable for medical use. The recombinant protein demonstrated significant adhesive properties for potential use in aqueous and medical environments.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Nutraceutical Astaxanthin Production Technology

Astaxanthin, a kind of lipid-soluble carotenoids pigment, is used as fish diets and supplements, and recently anticancer agent, and nutritional supplements in health food. This technology provides a process to increase the astaxanthin productivity by culturing microalgea while amount of light irradiation increase at constant speed.

Additional info in HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Device and Method for Detecting, Isolating and Eliminating Hazardous Microbiological Agents

A device for detecting, isolating and exterminating hazardous microbiological agents contained inside delicate objects such as envelopes and packages commonly used in worldwide mail and transport systems, which may be safely used in both business and residential locations, and which is very economical and easily manufactured.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Material for Buffered Resorbable Internal Fixation Devices and Method for Making Same

A bioerodible implantable material, comprising a bioerodible polymer that produces acidic products upon hydrolytic degradation, and a buffering compound that buffers the acidic products and maintains the local pH within a desired range. The buffer compound acts to reduce the inflammatory foreign body response generated by the acidic products and reduces the sterile abscess condition that occurs at the site of the bioerodible implant materials of the prior art. Materials made according to the invention may be used for internal fixation devices (IFDs) for bone repair.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Buffered Resorbable Internal Fixation Devices and Methods for Making Material Therefore

An internal fixation device and a bioerodible implantable material useful therefor comprise a bioerodible polymer that produces acidic products or low molecular weight resorbable fragments upon hydrolytic degradation, and a buffering or neutralizing agent in sufficiently high concentration to moderate the rate of change of pH of said bioerodible material during bioerosion. The buffering or neutralizing agent acts to reduce the inflammatory foreign body response generated by the acidic products and reduces the sterile abscess condition that occurs at the site of the bioerodible implant materials of the prior art. Internal fixation devices (IFDs) according to the invention are useful, for example, for the repair, replacement or reconstruction of damaged bone in any area of the body.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Bioerodible Polymeric Semi-Interpenetrating Network Alloys for Surgical Plates and Bone Cements, and Method for Making Same

A bioerodible polymeric semi-IPN alloy which comprises a first bioerodible polymer capable of producing acidic products upon hydrolytic degradation; a second bioerodible polymer, which provides a biopolymeric scaffolding or internal reinforcement; and optionally a buffering compound that buffers the acidic products within a desired pH range. In a preferred embodiment, the second bioerodible polymer comprises polypropylene fumarate (PPF), which is cross-linked, desirably by a vinyl monomer such as vinyl pyrrolidone (VP) to form the biopolymeric scaffolding which provides the semi-IPN with dimensional and geometric stability.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Bioerodible Polymeric Semi-Interpenetrating Network Alloys and Internal Fixation Devices Made Therefrom

A bioerodible cement system, which, upon mixing of the system parts, forms a cured bioerodible cement, said system comprising a first part comprising a first bioerodible polymer capable of producing acidic products upon hydrolytic degradation; and a second part comprising a second bioerodible scaffolding polymer which upon crosslinking provides a biopolymeric scaffolding or internal reinforcement for said cured cement is disclosed. In a preferred embodiment, the second bioerodible polymer comprises polypropylene fumarate (PPF), which is cross-linked during curing, desirably by a vinyl monomer such as vinyl pyrrolidone (VP) to form the biopolymeric scaffolding which provides the cured cement with dimensional and geometric stability.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Bioerodible Polymeric Semi-Interpenetrating Network Alloys for Internal Fixation Devices and Bone Cements

A bioerodible polymeric material, and in particular a semi-interpenetrating network ("semi-IPN") alloy, is disclosed. A beneficial end use of this material is in the form of internal fixation devices (IFDs) (such as bone supports, plates, and pins) and as cured bone cements for bone repair. A multi-part bioerodible cement system, which, upon mixing of the system parts, forms a cured bioerodible cement, includes, in one part, a first bioerodible polymer (e.g., PLGA) capable of producing acidic products upon hydrolytic degradation, and, in another part, a second bioerodible scaffolding polymer (e.g., PPF) which upon crosslinking provides a biopolymeric scaffolding or internal reinforcement for the cured cement. In another aspect, a bone cement system of the invention includes a bioerodible scaffolding polymer (such as PPF), which when polymerized provides a hardened bone cement, the cement system further including a gas generating agent in stabilized form for providing the cured bone cement with pores for facilitating inward cell migration.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Resorbable Interbody Spinal Fusion Devices

A resorbable interbody fusion device for use in spinal fixation is disclosed. The device is composed of 25-100% bioresorbable or resorbable material. The interbody fusion device of the invention can be in any convenient form, such as a wedge, screw or cage. Preferably, the resorbable device of the invention is in the shape of a tapered wedge or cone, which further desirably incorporates structural features such as serrations or threads better to anchor the device in the adjoining vertebrae. The preferred device further comprises a plurality of peripheral voids and more desirably a central void space therein, which may desirably be filled with a grafting material for facilitating bony development and/or spinal fusion, such as an autologous grafting material. As the preferred material from which the resorbable interbody fusion device is manufactured is most likely to be a polymer that can produce acidic products upon hydrolytic degradation, the device preferably further includes a neutralization compound, or buffer, in sufficiently high concentration to decrease the rate of pH change as the device degrades, in order to prevent sterile abscess formation caused by the accumulation of unbuffered acidic products in the area of the implant.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Method of Making a Biodegradable Interbody Spinal Fusion Devices

A resorbable interbody fusion device for use in spinal fixation is disclosed. The device is composed of 25-100% bioresorbable or resorbable material. The interbody fusion device of the invention can be in any convenient form, such as a wedge, screw or cage. Preferably, the resorbable device of the invention is in the shape of a tapered wedge or cone, which further desirably incorporates structural features such as serrations or threads better to anchor the device in the adjoining vertebrae. The preferred device further comprises a plurality of peripheral voids and more desirably a central void space therein, which may desirably be filled with a grafting material for facilitating bony development and/or spinal fusion, such as an autologous grafting material. As the preferred material from which the resorbable interbody fusion device is manufactured is most likely to be a polymer that can produce acidic products upon hydrolytic degradation, the device preferably further includes a neutralization compound, or buffer, in sufficiently high concentration to decrease the rate of pH change as the device degrades, in order to prevent sterile abscess formation caused by the accumulation of unbuffered acidic products in the area of the implant.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Tissue Transplant Coated With Biocompatible Biodegradable Polymer

A method by which immune responses to cortical bone grafts and other substrates (e.g., cement, IPN, etc.) can be minimized and at the same time graft osteoinductive potential can be improved, and improved graft substrate materials are disclosed. The method of the invention provides new types of bone grafts that incorporate into host bone more thoroughly and more rapidly, eliminating long-term complications, such as fracture, non-union, infection, and rejection. In the method of the invention, bone grafts or other substrates are modified to have an osteoinductive surface modification that the recipient's body will accept as its own tissue type and therefore will not reject or otherwise cause to fail. The osteoinductive surface modification comprises a biopolymer matrix coating that is seeded with periosteal cells that have been previously harvested either from the graft recipient or from an allogenic or xenogenic donor source.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Biodegradable Bursting Release System

A biodegradable polymeric multiphasic release system of one or more biodegradable bursting units capable of delivering biologically active substances in a burst or pulse at predetermined times and a method for constructing those units is disclosed. The individual bursting units of the system may take the form of a biodegradable, membrane coated capsule surrounding a core material which may include an active agent. The membrane ruptures after a predetermined time upon exposure to water or bodily, or other aqueous environmental fluids. The bursting units may be used in any situation in which a controlled pulsed release of an active substance is desired. The predetermined time release of each bursting unit is controlled by the composition of the core material, the initial radius and wall thickness of the membrane and the porosity of the membrane. The core material may also contain a chemical composition which generates gas as fluid is drawn into the bursting unit thus adding an additional design variable for predetermining bursts.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Method for Making a Bioerodible Material for the Sustained Release of a Medicament and the Material Made from the Method

A method for making an implantable bioerodible material for the sustained release of a medicament and the material made from the method. The method comprises the formulation of a biomaterial polymeric carrier into particles of predetermined density and size. The particles are then are mixed with the desired medicament and extruded into the desired shape for implantation or reground to a predetermined size distribution for injection as a suspension. In an alternative embodiment, the particles of polymeric carrier are immersed in a solvent containing a medicament, and the pores of the particles are filled with medicament through alternate application and release of vacuum.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Method of Making Biopolymer-Based Nonlinear Optical Materials

A biopolymer film and other materials that exhibit nonlinear optical (NLO) properties and a method for making this film. Alignment of biopolymer molecules, which is required for NLO phenomena, is achieved by application of an electric field parallel to the surface of a biopolymer solution as the film is formed. In one embodiment, a solution of poly(.gamma.-benzyl-L-glutamate), PBLG, in methylene chloride is employed. Upon application of an electric field, laminar structures perpendicular to both the field direction and to the film surface are formed. These ordered structures are captured in the film upon evaporation of the biopolymer solvent.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Optical Shutter Device

The present invention pertains to an optical shutter device comprising one or more photon absorbing materials that convert photons to heat in less than 1 nanosecond and one or more thermochromic materials that undergo an increase or decrease in optical density at one or more wavelengths when the thermochromic material is heated from 25.degree. C. to a temperature greater than 100.degree. C. in less than 1 nanosecond.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us


Contact Us    Biopolymer-Based Optical Element

Provided is an optical element comprising a biopolymer having an oriented structure and a photoresponsive compound, such as a photochromic compound, wherein at least a portion of the photoresponsive compound is incorporated within the oriented structure of the biopolymer and wherein the oriented structure is laminar with the planes of the laminar orientation being aligned perpendicular to a surface of the optical element. Preferably, the biopolymer is a liquid crystal polypeptide, such as ferroelectric liquid crystal poly(.gamma.-methyl-L-glutamate), and the photochromic compound is bacteriorhodopsin. Such optical elements may be utilized in a holographic grating, in an optical correlator system such as for pattern recognition, in a dynamic holographic recording system, and in an optical switch.

Download additional patent info in PDF Format or HTML Format
Interested parties call 1.617.283.2182 or Contact Us



* * * * *

 

Contact Us Contact Us to anonymously post your technology on our website - the biotech, chemistry, drug, healthcare, medical and related technology marketplace and clearinghouse.

Contact Us Contact Us for information about how MVS Solutions can develop, license, sell or acquire technologies on behalf of you and your organization.

All inquiries are held in the strictest of confidence. Nondisclosure and Confidentiality Agreements are available upon request.

Technology ClearinghouseVisit our Strategic Alliances & Partnering site for commercialization & partnering opportunities.


Visit MVSSolutions.com for info about our technology development services. Visit MVSSolutions.biz for info about our enterprise development & business services. Visit MVSSolutions.us for info about our government contractor services. MVS Solutions - Conducting the Business of Science and Technology (sm)

Conducting the Business of Science SM

HOME | WHO WE ARE | WHAT WE DO | AFFILIATIONS | CONTACT US | PRIVACY STATEMENT | JOBS | NEWS
CAPABILITIES | SITE MAP | COPYRIGHT AND TRADEMARK NOTICE | THE BUSINESS OF SCIENCE
TECHNICAL DUE DILIGENCE | REFERRALS - RECOMMENDATIONS | INTELLECTUAL PROPERTY
SITE SEARCH | WEB SEARCH | CONSULTANTS DIRECTORY | RESOURCES | EVENTS
INTERNATIONAL SITE | WIRELESS INTERNET SITE | MEDIA INFO
INDUSTRY NEWS FEEDS | CLIENT TESTIMONIALS
EXPERTISE | EXPERT WITNESS & CONSULTANT
EMERGING BUSINESS DEVELOPMENT
TECHNOLOGY COMMERCIALIZATION
COMPENSATION PHILOSOPHY
GREEN CHEMISTRY SUPPORT
BID - RFP - RFQ REQUESTS
COACHING & MENTORING
INDEPENDENT DIRECTOR
INVESTMENT BANKING
OUR MARKETS
OUR CLIENTS
MARKETING
US AGENT
IBEC

QUICK TOOLS


Resources:
Biotech | Chemistry | Medical Devices | Materials | Environmental | Engineering | Pharmaceutical | Green Chemistry | Technology Marketplace | Strategic Alliances & Partnering | Venture Capital & Funding | Grant Opportunities | Business | General | International | Search | Publications | Homeland Security | Web Directory | The Business of Science Newsletter


EMAIL

Deutsch | English | Español | Français | Italiano | Português




© 1999-2006 MVS Solutions Incorporated. All Rights Reserved.